Advantest Corp (ATE)

12.61
0.53 4.37
OTC : Technology
Prev Close 12.08
Open 12.60
Day Low/High 12.59 / 12.62
52 Wk Low/High 7.01 / 12.08
Volume 4.21K
Avg Volume 20.40K
Exchange OTC
Shares Outstanding 174.57M
Market Cap 1.71B
EPS 0.62
P/E Ratio N/A
Div & Yield 0.16 (1.70%)

Latest News

IIROC Trading Halt - ATE

IIROC Trading Halt - ATE

VANCOUVER, Feb. 4, 2019 /CNW/ - The following issues have been halted by IIROC: Company: ANTIBE THERAPEUTICS INC TSX-Venture Symbol: ATE Reason: At the Request of the Company Pending News Halt Time (ET): 3:53 PM IIROC can make a decision to impose a...

Antibe Therapeutics Receives Approval To Initiate Part Two Of Phase 2B Dose-Ranging, Efficacy Study For ATB-346

Antibe Therapeutics Receives Approval To Initiate Part Two Of Phase 2B Dose-Ranging, Efficacy Study For ATB-346

Antibe Therapeutics Inc. ("Antibe") (TSXV:ATE, OTCQB:ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce that it has received approval from Health Canada to initiate the second part of its Phase 2B...

Antibe Therapeutics Raises $1.6 Million Through Warrant Exercises

Antibe Therapeutics Raises $1.6 Million Through Warrant Exercises

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV:ATE, OTCQB:ATBPF), a leader in developing safer therapeutics for pain and inflammation, today announced that it has received gross proceeds of $1.

Antibe Therapeutics To Present At The 11th Annual LD Micro Main Event On December 4, 2018

Antibe Therapeutics To Present At The 11th Annual LD Micro Main Event On December 4, 2018

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV:ATE, OTCQB:ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce that it has been invited to present at the 11 th Annual LD Micro Main Event Investor...

Antibe Therapeutics Announces Successful Completion Of Part One Of Phase 2B Dose-Ranging, Efficacy Study For ATB-346

Antibe Therapeutics Announces Successful Completion Of Part One Of Phase 2B Dose-Ranging, Efficacy Study For ATB-346

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce the successful completion of part one of the Phase 2B dose-ranging, efficacy study...

Antibe Therapeutics Establishes Business Development Advisory Board

Antibe Therapeutics Establishes Business Development Advisory Board

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce that it has established a strategic advisory board to support its business...

Antibe Therapeutics Receives Approval To Initiate Part One Of Phase 2B Dose-Ranging, Efficacy Study For ATB-346

Antibe Therapeutics Receives Approval To Initiate Part One Of Phase 2B Dose-Ranging, Efficacy Study For ATB-346

Antibe Therapeutics Inc. ("Antibe") (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce that it has received approval from Health Canada to initiate the first part of its Phase 2B...

Antibe Therapeutics Announces Grant Of Restricted Share Units

Antibe Therapeutics Announces Grant Of Restricted Share Units

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV: ATE, OTCQB: ATBPF) announces that it has granted restricted share units ("RSUs") pursuant to the Company's RSU plan that was adopted at the most recent annual shareholder's meeting on June 25,...

Antibe Therapeutics Announces Strategic Licensing Deal For Lead Drug In South Korea

Antibe Therapeutics Announces Strategic Licensing Deal For Lead Drug In South Korea

Antibe Therapeutics Inc. ("Antibe") (TSXV:ATE, OTCQB:ATBPF), a leader in developing safer therapeutics for pain and inflammation, today announced that it has entered into an exclusive licensing agreement with Kwang Dong Pharmaceutical Co.

Antibe Therapeutics Reports Q1 2019 Interim Financial And Operating Results

Antibe Therapeutics Reports Q1 2019 Interim Financial And Operating Results

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Wednesday, August 29 th for the fiscal quarter ended June 30, 2018.

Antibe Therapeutics Provides Clinical Development Update On Its Lead Drug

Antibe Therapeutics Provides Clinical Development Update On Its Lead Drug

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to provide an update on its clinical development activities for its lead drug, ATB-346.

Antibe Completes Share Issuance In Connection With Citagenix Credit Facility

Antibe Completes Share Issuance In Connection With Citagenix Credit Facility

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV: ATE, OTCQB: ATBPF) announces that further to its release of June 29, 2018, it has issued to Bloom Burton Healthcare Lending Trust ("BBHLT") 578,572 common shares in the capital of Company...

Antibe Therapeutics Reports 2018 Year-End Financial And Operating Results

Antibe Therapeutics Reports 2018 Year-End Financial And Operating Results

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Friday, June 29 for the fourth quarter and the year ended March 31, 2018.

Antibe Therapeutics Announces Results Of Annual General And Special Meeting

Antibe Therapeutics Announces Results Of Annual General And Special Meeting

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV: ATE, OTCQB: ATBPF) is pleased to announce the results of its annual general and special meeting held yesterday.

Antibe's Chief Scientific Officer To Present At 5th World Congress On Hydrogen Sulfide In Biology And Medicine

Antibe's Chief Scientific Officer To Present At 5th World Congress On Hydrogen Sulfide In Biology And Medicine

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV: ATE, OTCQB: ATBPF) is pleased to announce that its Chief Scientific Officer, John Wallace, will deliver a lecture at the 5th World Congress on Hydrogen Sulfide in Biology and Medicine.

Calgary Researchers Discover A Novel Approach To Treatment Of Inflammatory Bowel Diseases (IBD) Using Hydrogen Sulfide Technology

Calgary Researchers Discover A Novel Approach To Treatment Of Inflammatory Bowel Diseases (IBD) Using Hydrogen Sulfide Technology

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV:ATE, OTCQB:ATBPF) is pleased to announce that a team of researchers at the University of Calgary has identified a key mechanism underlying the ability of certain intestinal bacteria to contribute...

Antibe Therapeutics To Present At Bloom Burton & Co. Healthcare Investor Conference

Antibe Therapeutics To Present At Bloom Burton & Co. Healthcare Investor Conference

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV: ATE, OTCQB: ATBPF) is pleased to announce that it will be presenting at the upcoming Bloom Burton & Co.

Antibe Therapeutics Announces CEO Letter To Shareholders

Antibe Therapeutics Announces CEO Letter To Shareholders

Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF): To our stakeholders, The recent success of our lead drug, ATB-346, in its Phase 2B gastrointestinal ("GI") safety clinical study was a significant milestone for Antibe and represented a major...

Antibe Therapeutics Provides Financial Update

Antibe Therapeutics Provides Financial Update

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV:ATE, OTCQB:ATBPF), a leader in developing safer therapeutics for pain and inflammation that recently announced a successful Phase 2B clinical trial demonstrating...

Antibe Therapeutics Announces Successful Phase 2B Gastrointestinal Safety Study For Lead Pain Drug, ATB-346

Antibe Therapeutics Announces Successful Phase 2B Gastrointestinal Safety Study For Lead Pain Drug, ATB-346

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV: ATE, OTCQB: ATBPF) is pleased to announce that its lead drug, ATB-346, met its primary endpoint in the Phase 2B gastrointestinal ("GI") safety study.

Antibe Therapeutics Announces No Material Change

Antibe Therapeutics Announces No Material Change

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV: ATE, OTCQB: ATBPF) wishes to advise that it is not aware of any undisclosed material change in the Company's activities that would account for recent market...

Antibe Therapeutics Reports Q3 2018 Interim Financial And Operating Results

Antibe Therapeutics Reports Q3 2018 Interim Financial And Operating Results

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Tuesday, February 27 th for the fiscal quarter ended December 31, 2017.

Antibe Therapeutics Provides Update On Phase 2B Gastrointestinal Safety Study Of Lead Pain Drug, ATB-346

Antibe Therapeutics Provides Update On Phase 2B Gastrointestinal Safety Study Of Lead Pain Drug, ATB-346

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV: ATE, OTCQB: ATBPF) would like to confirm the previously announced timing for its Phase 2B double-blind clinical trial of ATB-346.

Antibe Therapeutics Announces Enrollment Of Final Subjects In Phase 2B Gastrointestinal Safety Study Of Lead Pain Drug, ATB-346

Antibe Therapeutics Announces Enrollment Of Final Subjects In Phase 2B Gastrointestinal Safety Study Of Lead Pain Drug, ATB-346

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV: ATE, OTCQB: ATBPF), a diversified biotechnology company with two best-in-class divisions in pain/inflammation and regenerative medicine, is pleased to announce...

Antibe Therapeutics Engages Brand Institute To Advise On Nonproprietary Name For ATB-346

Antibe Therapeutics Engages Brand Institute To Advise On Nonproprietary Name For ATB-346

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV:ATE, OTCQB:ATBPF) is pleased to announce that it has engaged Brand Institute, Inc.

Antibe Therapeutics Reports Q2 2018 Interim Financial And Operating Results And Provides Corporate Update

Antibe Therapeutics Reports Q2 2018 Interim Financial And Operating Results And Provides Corporate Update

Antibe Therapeutics Inc. ("Antibe") (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Tuesday, November 28 th for the fiscal quarter ended September 30, 2017.

Antibe Therapeutics Announces Key US Distribution Partnership For Its Subsidiary, Citagenix

Antibe Therapeutics Announces Key US Distribution Partnership For Its Subsidiary, Citagenix

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV: ATE, OTCQB: ATBPF) is pleased to announce that its subsidiary, Citagenix Inc.

Antibe Therapeutics To Attend 2017 CPhI Worldwide Conference To Continue Partnering Discussions

Antibe Therapeutics To Attend 2017 CPhI Worldwide Conference To Continue Partnering Discussions

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV: ATE, OTCQB: ATBPF) will be attending the 2017 CPhI Worldwide conference next week in Frankfurt, Germany.